Clinical Trial

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2024 (before its estimated February 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-04.
Status change: Not Yet Recruiting → Recruiting 2024-04-09
Trial Details
NCT Number NCT06206174
Lead Sponsor Shenzhen TargetRx Co., Ltd.
Collaborators: Institute of Hematology & Blood Diseases Hospital, China
Conditions Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes
Enrollment 30 participants
Start Date 2024-03-06
Primary Completion 2025-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-04-10